Speaker Presentations
Our thanks to all of the presenters and attendees who contributed to the success of this year’s Symposium.
We are pleased to make available the Symposium presentations in PDF in the language in which they were delivered.
Some presentations have not been posted at the request of the authors.
Monday, April 4, 2011 - Concurrent Sessions |
||||
|
1100 – 1230 |
Concurrent Session A1: Evidence, Ethics, and Quality: Issues in Health Technology Assessment Methodology |
Ms. Katherine Duthie Dr. Maurice McGregor Dr. Aaron Tejani Dr. Ken Bassett Mr. Ciprian Jauca |
||
|
Concurrent Session A2: Evidence-Based Policy-Making: What Works? |
Dr. John Embil |
|||
|
Concurrent Session A3: HTA in Hospitals: Reflections and Perceptions |
Ms. Carmen Thompson |
|||
|
Concurrent Session A4: Behavioural Change |
Dr. Terryn Naumann |
|||
|
Concurrent Session A5: Health Economics |
Dr. Nick Bansback |
|||
|
Concurrent Session A6: Moving from Evidence to Practice |
Dr. Sarah Jennings Mr. Alan Cassels Dr. Bing Guo |
|||
|
Concurrent Session A7: Health Technology Assessment and Oncology |
Dr. Wendong Chen Ms. Zahra Musa Mr. Mike Paulden Dr. Paulos Teckle |
|||
|
1330 – 1500 |
Concurrent Session B1: PANEL DISCUSSION: Greater Than the Sum of Its Parts: Melding and Adapting Seven Guidelines |
Ms. Christa Harstall Dr. Carmen Moga Dr. Ann Scott Dr. Werner Becker |
||
|
|
Concurrent Session B2: PANEL DISCUSSION: Health Technology Assessment for Health System Sustainability: Opportunities and Challenges |
|||
|
|
Concurrent Session B3: PANEL DISCUSSION: Health Technology Assessment and Comparative Effectiveness Topic Development and Priority Setting: Overview of Canadian and International Processes |
Ms. Sandy Pagotto Dr. Reiner Banken |
||
|
|
Concurrent Session B4: PANEL DISCUSSION: Improving Health Outcomes and Health Care System Sustainability, and Encouraging Innovation by Collaborating with Industry |
Ms. Leah Clark |
||
|
|
Concurrent Session B6: PANEL DISCUSSION: How Can Decision-Makers Consider Other Factors in Decision-Making: Multi-Criteria to Maximize Opportunities to Bring Evidence into Practice? |
Dr. Janet Martin Dr. Tammy Clifford |
||
|
|
Concurrent Session B7: PANEL DISCUSSION: Openness in Health Technology Assessments |
Ms. Lynn Buchanan Dr. Andreas Laupacis Dr. Martin Zagari |
||
|
1530 – 1700 |
Concurrent Session C1: Decision-Maker Support |
Mr. Pavel Roshanov |
||
|
|
Concurrent Session C2: Pharmaceutical Issues |
Dr. Barbara Mintzes Mr. Shawn Bugden |
||
|
|
Concurrent Session C3: Emerging Technologies/ |
|||
|
|
Concurrent Session C4: Priority Setting and Resource Allocation |
|||
|
|
Concurrent Session C5: Evidence to Practice |
Dr. Alison Hoens |
||
|
|
Concurrent Session C6: |
Dr. Robin Turpin Dr. Mehdi Najafzadeh |
||
|
|
Concurrent Session C7: Evidence-Based Cost Savings |
Dr. Larry Lynd Dr. Jeffrey Hoch |
||
Tuesday, April 5, 2011 |
||||
|
0830 – 0945 |
Plenary Session: Maximizing Our Investment in Clinical Practice Guidelines |
Dr. Stirling Bryan Dr. Norman Campbell Dr. Scott Klarenbach Dr. Valerie Palda Dr. Martin Reed |
||
|
1015 – 1145 |
Concurrent Session D1: PANEL DISCUSSION: Value-Based Drug Reimbursement: Do We Want It? Do We Already Have It? |
Dr. Jeffrey Hoch |
||
|
Concurrent Session D2: PANEL DISCUSSION: The Drug Safety and Effectiveness Network (DSEN): Evidence for Informed Decisions |
Dr. Robert Peterson Mr. Bob Nakagawa Dr. Diane Forbes Dr. Christian Brochu Dr. Chris Turner Dr. Colin Dormuth |
|||
|
Concurrent Session D3: PANEL DISCUSSION: Using CADTH Recommendations for Self-Monitoring of Blood Glucose in Nova Scotia: Go Fast Alone or Go Far Together |
Dr. Michael Allen Ms. Peggy Dunbar Ms. Isobel Fleming Ms. Corinne Tobin Ms. Pam McLean-Veysey |
|||
|
Concurrent Session D4: PANEL DISCUSSION: Alberta Health Services and Advancing the Uptake of Health Technology Assessment and Innovation: An Update on Alberta’s Experience |
Ms. Rosmin Esmail Dr. Lea Austen Mr. Jitendra Prasad |
|||
|
Concurrent Session D5: PANEL DISCUSSION: CSI: A Café Scientifique Investigation †Using Café to Demystify Recommendations, Engage Audiences, and Address Barriers |
Dr. Adil Virani |
|||
|
1315 – 1445 |
Concurrent Session E1: PANEL DISCUSSION: Building Bridges: Regulatory Science and Reimbursement Decision-Making |
Dr. Stuart MacLeod |
||
|
|
Concurrent Session E2: PANEL DISCUSSION: Guideline Development: Overcoming Challenges of Limited Evidence and Implementation at a National Level |
Mr. Clarence Weppler Ms. Emma Irvin Dr. Michael Allen Dr. Norman Buckley |
||
|
|
Concurrent Session E3: PANEL DISCUSSION: Eyes Wide Open: Using Evidence to Rethink the Treatment Model for Type 2 Diabetes in Canada |
Mr. Chris Cameron |
||
|
|
Concurrent Session E4: PANEL DISCUSSION: Surrogate Markers in Health Technology Assessment: To Use or Not To Use Is the Question |
Dr. Charles Piwko Dr. Jeffery Hoch |
||
|
|
Concurrent Session E5: Public Engagement |
Mr. Harlon Davey |
||
|
|
Concurrent Session E6: Policy Issues Across Canada |
Dr. Aaron Tejani Mr. Sean Hardiman Dr. Joel Lexchin |
||
|
1500 – 1615 |
Closing Plenary: Maximizing Our Investment in Health Technologies |
Dr. Sarah Garner Dr. Clifflord Goodman Dr. Chris Henshall Ms. Diane McArthur Dr. Brian O’Rourke |
||
Some presentations have not been posted at the request of the authors.